QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Clinical trial NCT03853317 · TERMINATED
Trial details
- NCT number
- NCT03853317
- Sponsor
- ImmunityBio, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-19
- Primary completion
- 2021-09-29
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.